Late Preterm Steroid Therapy Found to Be Cost-Effective

Compared with no tx, costs lower when high-risk women given betamethasone in late preterm period

pregnancy exam

WEDNESDAY, April 3, 2019 (HealthDay News) -- In women at high risk for late preterm delivery, antenatal treatment with betamethasone is a cost-effective strategy, according to a study published online March 11 in JAMA Pediatrics.

Cynthia Gyamfi-Bannerman, M.D., from the Columbia University Medical Center in New York City, and colleagues used data from the Antenatal Late Preterm Steroids trial to compare the cost-effectiveness of treatment with antenatal corticosteroids to no treatment for women at risk for late preterm delivery. Participants included 1,426 mother-infant pairs in the betamethasone group and 1,395 mother-infant pairs in the placebo group.

The researchers found that treatment with betamethasone was associated with a total mean woman-infant pair cost of $4,681, which was significantly less than the mean cost of $5,379 for woman-infant pairs in the placebo group. The trial previously demonstrated that betamethasone use is effective with respect to decreased respiratory morbidity (a 2.9 percent decrease), yielding an incremental cost-effectiveness ratio of −23,986.

"Because late preterm birth comprises a large proportion of all preterm births, our findings have the potential for a large influence on public health," the authors write.

Abstract/Full Text (subscription or payment may be required)

Physician’s Briefing Staff

Physician’s Briefing Staff

Published on April 03, 2019

Read this Next
About UsOur ProductsCustom SolutionsHow it’s SoldOur ResultsDeliveryContact UsBlogPrivacy PolicyFAQ